CBD-Dominant Extracts Improve Autism Symptoms in Children Say New Medical Studies

新的医学研究表明,CBD优势提取物改善儿童自闭症症状

2022-01-04 05:30:09 Cannabis

本文共1823个字,阅读需5分钟

According to the Centers for Disease Control (CDC), around 1 in every 44 kids in the United States have an autism spectrum disorder. While most cases are caused by genetics, there are other possible factors at play too. These include being born to older parents, and having a child with autism spectrum disorder means that there is a 2-18% chance that another child will be born with it. While early diagnosis and intervention is helpful in managing and mitigating symptoms, there are still many children who grow up to be adults living with challenging symptoms of autism. Because autism affects the entire body, kids who end up growing to be adults with autism struggle with physical and mental health conditions. Some of these include depression, anxiety, chronic sleep issues, ADHD, epilepsy, schizophrenia, and so much more. The Medical Cost of Autism There are skyrocketing costs associated with raising a child with autism. On average, it costs around $60,000 a year during childhood with most of these costs going to special services as well as lost salaries because one or more parents need to take care of the children.  Meanwhile, it also has a serious impact on the economy. In 2015 alone, $268 billion was spent caring for individuals with autism in the United States; these figures are forecast to rise to $461 billion by 2025. How Cannabis Helps There is an increasing number of studies that show cannabis and its non-psychoactive compound, CBD, to be beneficial for treating children with autism spectrum disorder. Normalizing cannabis as an autism medication, instead of other conventional medications that have a lot of serious side effects, will be the key in helping more people live lives as normal as possible, despite being born with autism. The latest study, which was released in late December 2021, was from Istanbul in Turkey where researchers studied the use of CBD-dominant extracts among 23 adolescent participants who had mild to severe autism. “Main improvements of the treatment were as follows: a decrease in behavioral problems was reported in 10 patients (32.2%), an increase in expressive language was reported in patients (22.5%), improved cognition was reported in 4 patients (12.9%), an increase in social interaction was reported in 3 patients (9.6%), and a decrease in stereotypes was reported in 1 patient (3.2%). The parents reported improvement in cognition in patients who adhered to CBD-enriched cannabis treatment for over two years,” report the investigators. However, there were 6 patients that showed no significant changes in behavior. “Using lower doses of CBD and trace THC seems to be promising in managing behavioral problems associated with autism,” conclude the authors. Meanwhile, in June 2021, a similar study from Brazil showed that cannabinoids were promising for treating autism. Brazilian researchers reviewed 9 clinical trials that analyzed the impact of cannabinoids in patients with autism spectrum disorder. The participants in 5 of the studies were given plant-derived oil extracts, while 2 studies focused on only the use of CBD; one study assessed CBDV (cannabidivarin) while the last one analyzed the use of oral THC in dronabinol form. Positive changes in the symptoms of autism were identified after administering cannabinoids, such as “decreased bouts of self-mutilation and anger, hyperactivity, sleep problems, anxiety, restlessness, psychomotor agitation, irritability, perseverance, aggressiveness, and depression and improvement in sensory sensitivity, cognition, attention, social interaction, and language.” In addition, any side-effects were reported to range from mild to moderate. “Cannabis and cannabinoids have very promising effects in the treatment of autistic symptoms and can be used in the future as an important therapeutic alternative,” the authors concluded. In 2019, a study this time from Israel proves that cannabis can be a beneficial treatment for kids under 18 who suffer from autism. Investigators from the Ben-Gurion University of the Negev, together with the Soroka University Medical Center, found that 80% of participants showed some level of improvement following 6 months of treatment with cannabis. “We analyzed the data prospectively collected as part of the treatment program of 188 ASD patients with medical cannabis between 2015 and 2017. The treatment in majority of the patients was based on cannabis oil containing 30% cannabidiol oil (CBD) and 1.5 tetrahydrocannabinol (THC). Symptoms, patient global assessment and side effects at six months were primary outcomes of interest and were assessed by structured questionnaires,” explains Dr. Gal Meiri from the Negev Autism Center. Specifically, they found that 30% of patients saw significant improvement after 6 months of treatment, 53.7% saw moderate beneficial changes, while 15% had a slight or no change. Additionally, the study examined the benefits of cannabis on the quality of life of the participants. The researchers looked at mood, quality of life, and their ability to do activities pertaining to daily living before treatment as well as after 6 months. Before treatment, 31.3% of patients reported good quality of life which doubled to 66.8% after 6 months; they also found that positive mood was experienced by patients at 42% prior to treatment, then it rose to 63.5% after 6 months. On top of that, the findings revealed that using cannabis oil was beneficial for improving concentration and sleep. “While this study suggest that cannabis treatment is safe and can improve ASD symptoms and improve ASD patients’ quality of life, we believe that double blind placebo-controlled trials are crucial for a better understanding of the cannabis effect on ASD patients,” says Dr. Victor Novack, from the BGU-Soroka Clinical Cannabis Research Institute. With a majority of the studies showing helpful improvements, it’s certainly a medication that parents can consider for their children with the guidance of a physician. DALE JACKSON ON COLIN'S VOICE CBDCANNABIS DROPS FOR HIS SON! WORLD'S LARGEST STUDY OF KIDS WITH AUTISM AND CANNABIS!
根据疾病控制中心(CDC)的数据,在美国,大约每44个孩子中就有一个患有自闭症谱系障碍。 虽然大多数病例是由遗传引起的,但也有其他可能的因素在起作用。其中包括父母年龄较大,有一个患有自闭症谱系障碍的孩子意味着有2-18%的机会生下另一个孩子。虽然早期诊断和干预有助于管理和减轻症状,但仍有许多儿童长大后患有挑战性的自闭症症状。 因为自闭症影响到整个身体,所以最终成长为成人的自闭症儿童会与身体和心理健康状况作斗争。其中一些包括抑郁、焦虑、慢性睡眠问题、多动症、癫痫、精神分裂症等等。 孤独症的医疗费用 抚养一个自闭症儿童的成本飙升。平均而言,儿童时期每年花费约6万美元,其中大部分费用用于特殊服务,以及因父母一方或多人需要照顾孩子而损失的工资。 同时,也对经济产生了严重影响。仅在2015年,美国就有2680亿美元用于照顾自闭症患者;这些数字预计到2025年将上升到4610亿美元。 大麻有什么帮助 越来越多的研究表明,大麻及其非精神活性化合物CBD对治疗自闭症谱系障碍儿童有益。将大麻作为自闭症药物正常化,而不是其他有许多严重副作用的传统药物,将是帮助更多人尽可能正常生活的关键,尽管他们生来就患有自闭症。 最新的研究于2021年12月下旬发布,来自土耳其伊斯坦布尔,研究人员在23名患有轻度至重度自闭症的青少年参与者中研究了CBD主导提取物的使用。“治疗的主要改善如下:10名患者的行为问题减少(32.2%),表达语言增加(22.5%),认知改善4名患者(12.9%),社会交往增加3名患者(9.6%),刻板印象减少1名患者(3.2%)。研究人员报告说:“父母报告说,坚持CBD富集大麻治疗两年多的患者认知能力有所改善。” 但有6例患者没有表现出明显的行为改变。 “使用低剂量的CBD和微量四氢大麻酚似乎有希望管理自闭症相关的行为问题,”作者总结道。 与此同时,2021年6月,巴西的一项类似研究表明,大麻素有望治疗自闭症。巴西研究人员回顾了9项临床试验,这些试验分析了大麻素对自闭症谱系障碍患者的影响。其中5项研究的参与者被给予植物源油提取物,而2项研究只关注CBD的使用;一项研究评估了CBDV(大麻静脉曲张素),而最后一项研究分析了屈大麻酚形式的口服四氢大麻酚的使用。 服用大麻素后,自闭症症状出现了积极的变化,如“减少了自残和愤怒、多动、睡眠问题、焦虑、不安、精神运动性躁动、易怒、毅力、攻击性和抑郁,以及感官敏感性、认知、注意力、社会交往和语言的改善。”此外,据报道,任何副作用从轻度到中度不等。 “大麻和大麻素在治疗自闭症症状方面有非常有希望的效果,在未来可以作为一种重要的治疗替代方案,”作者总结道。 2019年,这次来自以色列的一项研究证明,大麻对18岁以下患有自闭症的儿童来说是一种有益的治疗方法。内盖夫本-古里安大学和索罗卡大学医学中心的调查人员发现,80%的参与者在接受6个月的大麻治疗后表现出一定程度的改善。 “我们分析了作为2015年至2017年间188名服用医用大麻的自闭症患者治疗计划的一部分前瞻性收集的数据。大多数患者的治疗是以含有30%大麻二酚油(CBD)和1.5%四氢大麻酚(THC)的大麻油为基础的。Negev自闭症中心的Gal Meiri博士解释说:“症状、患者全球评估和六个月的副作用是主要的感兴趣结果,并通过结构化问卷进行评估。” 具体来说,他们发现30%的患者在治疗6个月后出现显著改善,53.7%的患者出现中度有益变化,而15%的患者出现轻微或无变化。此外,这项研究检查了大麻对参与者生活质量的好处。研究人员观察了治疗前和治疗后6个月的情绪、生活质量和日常生活相关活动的能力。治疗前31.3%的患者报告生活质量良好,6个月后增加了一倍,达到66.8%;他们还发现,患者在治疗前有42%的积极情绪,6个月后上升到63.5%。 最重要的是,研究结果表明,使用大麻油有利于提高注意力和睡眠。 BGU-Soroka临床大麻研究所的维克多·诺瓦克博士说:“虽然这项研究表明大麻治疗是安全的,可以改善自闭症症状,提高自闭症患者的生活质量,但我们认为双盲安慰剂对照试验对于更好地理解大麻对自闭症患者的影响至关重要。” 随着大多数研究显示出有益的改善,这当然是父母可以在医生的指导下为他们的孩子考虑的药物。 戴尔·杰克逊在科林的声音中为他的儿子滴大麻! 世界上最大的自闭症儿童和大麻研究!

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文